Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis

The Lancet Respiratory Medicine

Volumn 5, Issue 3, 2017, Pages 191-199

  Kendall, Emily A ^a   Fojo, Anthony T ^a   Dowdy, David W ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIAL TRANSMISSION; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HUMAN; INCIDENCE; LONG TERM CARE; MULTIDRUG RESISTANT TUBERCULOSIS; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; CLINICAL PROTOCOL; DRUG ADMINISTRATION; FORECASTING; PROCEDURES; SOUTHEAST ASIA; THEORETICAL MODEL; TIME FACTOR; TRANSMISSION; TREATMENT OUTCOME;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; ASIA, SOUTHEASTERN; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FORECASTING; HUMANS; INCIDENCE; MODELS, THEORETICAL; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85007529904     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30423-4     Document Type: Article

References (35)

1. 1 Global tuberculosis report 2015, 2015, World Health Organization, Geneva.
2. 2 Falzon, D, Mirzayev, F, Wares, F, et al. Multidrug-resistant tuberculosis around the world: what progress has been made?. Eur Respir J 45 (2015), 150–160.
3. 3 Ahuja, SD, Ashkin, D, Avendano, M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med, 9, 2012, e1001300.
4. 4 Toczek, A, Cox, H, du Cros, P, Cooke, G, Ford, N, Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 17 (2013), 299–307.
5. 5 Zignol, M, Dean, AS, Alikhanova, N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 16 (2016), 1185–1192.
6. 6 Cegielski, JP, Dalton, T, Yagui, M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 59 (2014), 1049–1063.
7. 7 Laurence, YV, Griffiths, UK, Vassall, A, Costs to health services and the patient of treating tuberculosis: a systematic literature review. Pharmacoeconomics 33 (2015), 939–955.
8. 8 WHO. WHO treatment guidelines for drug-resistant tuberculosis (2016 update), 2016, World Health Organization, Geneva http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en (accessed July 13, 2016).
9. 9 Aung, KJM, Van Deun, A, Declercq, E, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 18 (2014), 1180–1187.
10. 10 Piubello, A, Harouna, SH, Souleymane, MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 18 (2014), 1188–1194.
11. 11 Kuaban, C, Noeske, J, Rieder, HL, Aït-Khaled, N, Abena Foe, JL, Trébucq, A, High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 19 (2015), 517–524.
12. 12 Kuaban, C, Kashongwe, Z, Bakayoko, A, et al. First results with a 9-month regimen for multidrug-resistant tuberculosis (MDR-TB) in francophone Africa. The 46th Union World Conference on Lung Health; Cape Town, South Africa; Dec 2–6. http://html5.slideonline.eu/event/15UNION/presentation/56af80efdf14e7dc122045e5/480/4:3/first-results-with-a-9-month-regimen-for-multidrug-resistant-tuberculosis-mdr-tb-in-francophone-africa-english, 2015 (accessed Nov 8, 2016).
13. 13 WHO. Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions. Version 20 June 2016, 2016, World Health Organization, Geneva http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/FAQshorter_MDR_regimen.pdf (accessed July 13, 2016).
14. 14 Moodley, R, Godec, TR, STREAM Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev 25 (2016), 29–35.
15. 15 Sotgiu, G, Tiberi, S, D'Ambrosio, L, et al. Faster for less: the new ‘shorter’ regimen for multidrug-resistant tuberculosis. Eur Respir J 48 (2016), 1503–1507.
16. 16 Sotgiu, G, Tiberi, S, D'Ambrosio, L, Centis, R, Zumla, A, Migliori, GB, WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 387 (2016), 2486–2487.
17. 17 Kendall, EA, Fofana, MO, Dowdy, DW, Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med 3 (2015), 963–972.
18. 18 Dowdy, DW, Chaisson, RE, Maartens, G, Corbett, EL, Dorman, SE, Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci USA 105 (2008), 11293–11298.
19. 19 Menzies, D, Benedetti, A, Paydar, A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med, 6, 2009, e1000146.
20. 20 Vynnycky, E, Fine, PE, The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 119 (1997), 183–201.
21. 21 Andrews, JR, Noubary, F, Walensky, RP, Cerda, R, Losina, E, Horsburgh, CR, Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 54 (2012), 784–791.
22. 22 Fox, GJ, Barry, SE, Britton, WJ, Marks, GB, Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 41 (2013), 140–156.
23. 23 Holtz, TH, Sternberg, M, Kammerer, S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 144 (2006), 650–659.
24. 24 Grandjean, L, Gilman, RH, Martin, L, et al. Transmission of multidrug-resistant and drug-susceptible tuberculosis within households: a prospective cohort study. PLoS Med, 12, 2015, e1001843.
25. 25 Kurbatova, EV, Dalton, T, Ershova, J, et al. Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries. Emerg Infect Dis 21 (2015), 977–983.
26. 26 FIND-negotiated product pricing. Geneva: FIND. http://www.finddx.org/pricing/ (accessed July 26, 2016).
27. 27 Brossier, F, Guindo, D, Pham, A, et al. Performance of the new version (v2.0) of the GenoType MTBDRsl test for detection of resistance to second-line drugs in multidrug-resistant Mycobacterium tuberculosis complex strains. J Clin Microbiol 54 (2016), 1573–1580.
28. 28 Kamal, SMM, Hossain, A, Sultana, S, et al. Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey. Int J Tuberc Lung Dis 19 (2015), 151–156.
29. 29 Rao, NA, Irfan, M, Soomro, MM, Mehfooz, Z, Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients. J Coll Physicians Surg Pak 20 (2010), 262–265.
30. 30 Tiemersma, EW, van der Werf, MJ, Borgdorff, MW, Williams, BG, Nagelkerke, NJD, Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One, 6, 2011, e17601.
31. 31 Sachdeva, KS, Raizada, N, Gupta, RS, et al. The potential impact of up-front drug sensitivity testing on India's epidemic of multi-drug resistant tuberculosis. PLoS One, 10, 2015, e0131438.
32. 32 Cegielski, JP, Kurbatova, E, van der Walt, M, et al. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis 62 (2016), 418–430.
33. 33 Falzon, D, Gandhi, N, Migliori, GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 42 (2013), 156–168.
34. 34 Isaakidis, P, Das, M, Kumar, AMV, et al. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India. PLoS One, 9, 2014, e110461.
35. 35 Skrahina, A, Hurevich, H, Zalutskaya, A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 39 (2012), 1425–1431.